EHA 2024: Updates in the Treatment of CLL - Episode 15
Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice
A medical expert offers commentary on the recent FDA accelerated approval of pirtobrutinib, discussing the implications of the BRUIN trial findings that supported this decision for chronic lymphocytic leukemia treatment.
Video content above is prompted by the following questions:
- Briefly comment on the recent FDA accelerated approval granted to pirtobrutinib based on findings from BRUIN.
- How are you currently using pirtobrutinib in the clinical practice setting and how do you sequence it with other available therapies?
- Is there a potential role for pirtobrutinib in earlier lines of therapy?
Related Content:
